MKGAF
Price
$139.71
Change
-$2.04 (-1.44%)
Updated
Oct 7 closing price
Capitalization
60.71B
NPPNY
Price
$5.62
Change
+$0.39 (+7.46%)
Updated
Oct 2 closing price
Capitalization
1.49B
Interact to see
Advertisement

MKGAF vs NPPNY

Header iconMKGAF vs NPPNY Comparison
Open Charts MKGAF vs NPPNYBanner chart's image
Merck KGaA
Price$139.71
Change-$2.04 (-1.44%)
Volume$290
Capitalization60.71B
Nippon Shinyaku
Price$5.62
Change+$0.39 (+7.46%)
Volume$4.3K
Capitalization1.49B
MKGAF vs NPPNY Comparison Chart in %
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MKGAF vs. NPPNY commentary
Oct 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MKGAF is a Hold and NPPNY is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 09, 2025
Stock price -- (MKGAF: $141.90 vs. NPPNY: $5.62)
Brand notoriety: MKGAF and NPPNY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: MKGAF: 4% vs. NPPNY: 316%
Market capitalization -- MKGAF: $60.71B vs. NPPNY: $1.49B
MKGAF [@Pharmaceuticals: Generic] is valued at $60.71B. NPPNY’s [@Pharmaceuticals: Generic] market capitalization is $1.49B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MKGAF’s FA Score shows that 1 FA rating(s) are green whileNPPNY’s FA Score has 2 green FA rating(s).

  • MKGAF’s FA Score: 1 green, 4 red.
  • NPPNY’s FA Score: 2 green, 3 red.
According to our system of comparison, NPPNY is a better buy in the long-term than MKGAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MKGAF’s TA Score shows that 5 TA indicator(s) are bullish while NPPNY’s TA Score has 5 bullish TA indicator(s).

  • MKGAF’s TA Score: 5 bullish, 4 bearish.
  • NPPNY’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both MKGAF and NPPNY are a good buy in the short-term.

Price Growth

MKGAF (@Pharmaceuticals: Generic) experienced а -0.83% price change this week, while NPPNY (@Pharmaceuticals: Generic) price change was +7.46% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.16%. For the same industry, the average monthly price growth was +5.42%, and the average quarterly price growth was +62.58%.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.16% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($60.7B) has a higher market cap than NPPNY($1.49B). MKGAF has higher P/E ratio than NPPNY: MKGAF (18.39) vs NPPNY (6.99). MKGAF YTD gains are higher at: -6.371 vs. NPPNY (-15.361). NPPNY has higher annual earnings (EBITDA): 36.5B vs. MKGAF (5.87B). NPPNY has more cash in the bank: 66B vs. MKGAF (1.57B). NPPNY has less debt than MKGAF: NPPNY (2.55B) vs MKGAF (9.4B). NPPNY has higher revenues than MKGAF: NPPNY (154B) vs MKGAF (21.2B).
MKGAFNPPNYMKGAF / NPPNY
Capitalization60.7B1.49B4,088%
EBITDA5.87B36.5B16%
Gain YTD-6.371-15.36141%
P/E Ratio18.396.99263%
Revenue21.2B154B14%
Total Cash1.57B66B2%
Total Debt9.4B2.55B369%
FUNDAMENTALS RATINGS
MKGAF vs NPPNY: Fundamental Ratings
MKGAF
NPPNY
OUTLOOK RATING
1..100
2938
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7018
PRICE GROWTH RATING
1..100
5155
P/E GROWTH RATING
1..100
8386
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NPPNY's Valuation (7) in the null industry is in the same range as MKGAF (24). This means that NPPNY’s stock grew similarly to MKGAF’s over the last 12 months.

NPPNY's Profit vs Risk Rating (100) in the null industry is in the same range as MKGAF (100). This means that NPPNY’s stock grew similarly to MKGAF’s over the last 12 months.

NPPNY's SMR Rating (18) in the null industry is somewhat better than the same rating for MKGAF (70). This means that NPPNY’s stock grew somewhat faster than MKGAF’s over the last 12 months.

MKGAF's Price Growth Rating (51) in the null industry is in the same range as NPPNY (55). This means that MKGAF’s stock grew similarly to NPPNY’s over the last 12 months.

MKGAF's P/E Growth Rating (83) in the null industry is in the same range as NPPNY (86). This means that MKGAF’s stock grew similarly to NPPNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MKGAFNPPNY
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
Bearish Trend 2 days ago
41%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
68%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
31%
MACD
ODDS (%)
Bullish Trend 2 days ago
59%
Bullish Trend 2 days ago
32%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
28%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
25%
Advances
ODDS (%)
Bullish Trend 8 days ago
57%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
64%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
41%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
21%
View a ticker or compare two or three
Interact to see
Advertisement
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRDO35.100.47
+1.36%
Perdoceo Education Corp
XTNT0.680.01
+1.30%
Xtant Medical Holdings
MOVE0.680.01
+0.92%
Movano Inc
UNM78.620.36
+0.46%
Unum Group
UMAC15.64-0.35
-2.19%
Unusual Machines

MKGAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MKGAF
1D Price
Change %
MKGAF100%
+1.57%
MKKGY - MKGAF
49%
Loosely correlated
+1.30%
AQST - MKGAF
19%
Poorly correlated
+3.85%
INDV - MKGAF
17%
Poorly correlated
+1.48%
EVO - MKGAF
17%
Poorly correlated
+1.53%
EBS - MKGAF
16%
Poorly correlated
-0.30%
More

NPPNY and

Correlation & Price change

A.I.dvisor tells us that NPPNY and MEDIF have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NPPNY and MEDIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPPNY
1D Price
Change %
NPPNY100%
N/A
MEDIF - NPPNY
11%
Poorly correlated
+7.28%
OVATF - NPPNY
10%
Poorly correlated
N/A
OMID - NPPNY
3%
Poorly correlated
N/A
OILFF - NPPNY
-1%
Poorly correlated
-11.20%
MKGAF - NPPNY
-1%
Poorly correlated
+1.57%
More